MetaVia Announces Completion of Last Patient Visit in Extended 24-Week Phase 1 Part 3A Study of DA-1726
<p>Encouraging Preliminary Safety and Tolerability Observations in Part 3A Supported Decision to Extend Treatment from 16 to 24 Weeks Positive Part 3B Interim Data Presented at Precision Liver Symposium Demonstrated Statistically Significant 68.1% Placebo-Adjusted Reduction in Liver Fat Full...</p>
Read original article ↗
Related Articles
Not even Sam Altman is safe from AI deepfakes on Instagram
Open AI CEO Sam Altman does a television interview | Getty Images Instagram is filled with people posting deepfaked co
Instagram is helping creators crack down on copycat videos
Instagram is beginning to roll out a "content protection" feature that lets creators see and review copies of their vide
Meta is testing a new standalone messaging app called Direct
Meta announced Direct, a new messaging app from Instagram that it's currently testing in Turkey and Thailand on iOS and
Banning phones really does help kids learn, researchers say
A new nationwide study found that in-school cellphone bans can lead to modest improvements in learning. Now, researchers